Mentari Therapeutics AI Stock Analysis
Want to see MTRI full AI Analyst Report?
Mentari Therapeutics (MTRI) AI Stock Analysis
Mentari Therapeutics
(NASDAQ:MTRI)
The score is held down primarily by weak financial performance (ongoing losses, heavy cash burn, and negative equity). Technicals are modestly supportive with price above key moving averages and positive MACD, and corporate events are a near-term positive due to significant financing and Nasdaq listing, but valuation remains constrained by negative earnings and no indicated dividend.
Mentari Therapeutics Key Performance Indicators (KPIs)
Revenue By SegmentShows how much revenue each business segment generates, highlighting the company's strengths and potential areas for growth or concern based on segment performance.
BayMedica, a segment of InMed Pharmaceuticals, has shown a volatile revenue trajectory with significant growth spikes, notably in mid-2023, followed by fluctuations. Despite a peak in Q2 2023, recent quarters indicate a stabilization trend, suggesting efforts to maintain consistent revenue streams. The InMed segment, however, has consistently reported zero revenue, highlighting a potential strategic focus on BayMedica's performance. Investors should watch for strategic updates or market developments that could impact BayMedica's revenue stability and InMed's future contributions.
The FlyMentari Therapeutics (MTRI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $8.55M
- Dividend Yield
- ―
- Average Volume (3M)
- 10.10K
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 2.96
- Revenue Growth
- -82.91%
- EPS Growth
- 55.05%
- Country
- US
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Shell Companies
Mentari Therapeutics Business Overview & Revenue Model
Company Description
Operating within the United States, Metro Inc. specializes in the information security and education sectors. The company provides a comprehensive suite of security solutions, encompassing information security and privacy, physical security, investig...
Mentari Therapeutics Financial Statement Overview
Summary
Financial statement quality is poor: profitability remains negative despite a 2026 revenue jump, TTM revenue is down ~5.4%, and cash flow is deeply negative with substantial ongoing burn. The TTM balance sheet shows negative shareholders’ equity, indicating weakened capitalization and elevated financial risk, even though reported debt is minimal.
Income Statement
18Very NegativeBalance Sheet
22NegativeCash Flow
12Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.06B | 3.18B | 4.94M | 4.60M | 4.14M | 1.09M |
| Gross Profit | 306.74M | 709.84M | 1.71M | 1.10M | 1.40M | 543.55K |
| EBITDA | -9.31M | -9.19M | -7.26M | -7.06M | -7.34M | -18.09M |
| Net Income | -12.41M | -12.56M | -8.16M | -7.68M | -7.95M | -18.60M |
Balance Sheet | ||||||
| Total Assets | 1.31M | 3.03M | 15.58M | 11.82M | 14.11M | 12.79M |
| Cash, Cash Equivalents and Short-Term Investments | 1.13B | 2.23M | 11.08M | 6.57M | 8.91M | 6.22M |
| Total Debt | 0 | 0 | 741.00K | 963.00K | 392.00K | 794.00K |
| Total Liabilities | 2.51M | 1.96M | 2.15M | 2.62M | 2.02M | 3.71M |
| Stockholders Equity | -1.20M | 1.08M | 13.43M | 9.21M | 12.09M | 9.08M |
Cash Flow | ||||||
| Free Cash Flow | -9.04M | -8.64B | -7.77M | -7.00M | -7.45M | -15.62M |
| Operating Cash Flow | -9.04M | -8.64B | -7.77M | -6.99M | -7.28M | -15.58M |
| Investing Cash Flow | 2,417 | 0 | 0 | -9,293 | -661.80K | -673.00K |
| Financing Cash Flow | 271.81K | 94.50M | 12.27M | 4.65M | 10.68M | 15.07M |
Mentari Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTRI, the sentiment is Positive. The current price of 15.61 is above the 20-day moving average (MA) of 14.71, above the 50-day MA of 13.95, and above the 200-day MA of 12.14, indicating a bullish trend. The MACD of 0.57 indicates Negative momentum. The RSI at 53.95 is Neutral, neither overbought nor oversold. The STOCH value of 46.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MTRI.
Mentari Therapeutics Risk Analysis
Mentari Therapeutics disclosed 82 risk factors in its most recent earnings report. Mentari Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksMentari Therapeutics Peers Comparison
Overall Rating
- MTRI50Neutral
ADXN47Neutral
CLGN43Neutral
ENVB42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| MTRI | 50Neutral | $6.70M | -0.50 | -303.50% | ― | -82.91% | 55.05% |
| ADXN | 47Neutral | $3.31M | -0.46 | -172.76% | ― | -45.76% | -3.77% |
| CLGN | 43Neutral | $7.38M | -0.42 | -215.58% | ― | -86.76% | 16.63% |
| ENVB | 42Neutral | $6.76M | -0.09 | -168.05% | ― | ― | 87.05% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MTRI | Mentari Therapeutics, Inc. | 15.61 | -2.49 | -13.76% | |
| CLGN | CollPlant Biotechnologies Ltd. | 3.96 | -15.84 | -80.00% | |
| ENVB | Enveric Biosciences, Inc. | 1.49 | -3.97 | -72.71% | |
| SILO | Silo Pharma Inc | 1.84 | -4.69 | -71.79% | |
| ADXN | Addex Therapeutics Ltd (ADR) | 2.77 | -5.83 | -67.85% |
Mentari Therapeutics Corporate Events
InMed Pharmaceuticals Completes Merger, Begins Nasdaq Trading
PositiveOn November 9, 2026, Mentari Therapeutics completed its previously disclosed merger with InMed Pharmaceuticals, adopted the Mentari name and began trading on Nasdaq Capital Market under MTRI. The transaction marked the company’s entry into public mar...
InMed Pharmaceuticals Completes Share Consolidation and Name Change
NeutralOn November 4, 2026, shareholders approved the matters presented at the annual general and special meeting, with 3,630,088 shares, or 66.08% of outstanding shares, represented. The votes approved merger-related Nasdaq share issuance and change of con...
InMed Pharmaceuticals Completes Share Consolidation and Name Change
NeutralOn November 4, 2026, shareholders approved proposals covering merger-related share issuance and change of control, return of capital, redomestication to Nevada, new stock and employee purchase plans, and merger compensation. They also elected five di...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026